NeuroSense Winding Up Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023

 

• Clinical efficacy results (secondary endpoints) and safety results (primary endpoints) expected December 2023
• Biogen collaboration biomarker results expected Q1 2024
• Primary biomarker endpoints to be reported H1 2024 

https://www.biospace.com/article/releases/neurosense-completes-dosing-of-last-patient-in-the-double-blind-segment-of-phase-2b-als-trial-topline-clinical-efficacy-results-expected-december-2023/